Skip to content
← Full study record

NCT02516696 · MORE INFO

Limitations, agreements, and source contact

BiRd vs. Rd as Initial Therapy in Multiple Myeloma · Source last updated 2023-06-05

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
pi Sponsor Employee
true
restrictive Agreement
false
limitations And Caveats
description
The significance of these results is limited by the study's low accrual. The study's low accrual was due in part to the COVID-19 pandemic.
point Of Contact
email
hyk4001@med.cornell.edu
organization
Weill Cornell Medicine
phone
646.962.9376
title
Multiple Myeloma Program Manager
Complete source fields
certain Agreement
pi Sponsor Employee
true
restrictive Agreement
false
limitations And Caveats
description
The significance of these results is limited by the study's low accrual. The study's low accrual was due in part to the COVID-19 pandemic.
point Of Contact
email
hyk4001@med.cornell.edu
organization
Weill Cornell Medicine
phone
646.962.9376
title
Multiple Myeloma Program Manager

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice